Incidence of sarcopenia and dynapenia according to stage in patients with idiopathic Parkinson’s disease


Yazar T., Yazar H. O., Zayimoğlu E., Çankaya S.

Neurological Sciences, cilt.39, sa.8, ss.1415-1421, 2018 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 39 Sayı: 8
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1007/s10072-018-3439-6
  • Dergi Adı: Neurological Sciences
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1415-1421
  • Anahtar Kelimeler: Dynapenia, Idiopathic Parkinson’s disease, Sarcopenia
  • Ondokuz Mayıs Üniversitesi Adresli: Evet

Özet

Aim: In this study, the aim was to identify the incidence of sarcopenia and dynapenia according to disease stage among idiopathic Parkinson’s disease (IPD) patients and collect data to illuminate precautions related to reducing the disease load. Method: The study was completed with 166 patients divided by stage according to modified Hoehn and Yahr (HYR) criteria and 249 healthy volunteers aged from 18 to 39 and 68 to 75 years met the inclusion criteria. In our prospective and cross-sectional study, patients with IPD according to “UK Brain Bank” diagnostic criteria had the Unified Parkinson’s Disease Rating Scale (UPDRS) and HYR scales applied. The patient and control groups had skeletal muscle mass index (SMMI), muscle power, and physical performance assessed. Diagnosis of sarcopenia used the European Working Group on Sarcopenia in Older People (EWGSOP) diagnostic criteria. Results: In our study, in parallel with the increase in disease stage among IPD patients, the incidence of sarcopenia (led by severe sarcopenia) and dynapenia was high compared to that among the control group of the same age. Conclusion: In the early stages of chronic progressive diseases like IPD, identification of sarcopenia and dynapenia is important considering the limitations of disease-preventive effects in treatments applied after diagnosis.